New pill shrinks lung tumors before surgery in early trial
NCT ID NCT07156604
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 24 times
Summary
This study tests a drug called Vebreltinib given for 8 weeks before surgery in people with a specific type of lung cancer (stage IIA-IIIB NSCLC with METex14 skipping mutation). The goal is to see if the drug can shrink or control the tumor, making surgery more effective. About 30 participants will take the pill twice daily, then have surgery, and be followed for up to 3 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center, Shanghai,
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.